Yeast Biotech Closes Tens of Millions Series A to Scale Natural DHA/EPA Output
Release date:
2025-03-10 12:39
Share:
Recently, Yeast Biotech a technology innovation enter prise focused on synthetic biology, announced the completion of a tens of millions of yuan Series A financing round, with participation from Zijin Capital. Leveraging enzyme engineering and metabolic engineering technologies, Yeast Biotech provides green manufacturing solutions for the pharmaceutical, food, health food, and cosmetics industries. Its product portfolio includes DHA/EPA derived from algal and fish oils, diacylglycerols, and structured lipids.
The raised funds will be primarily used for building a thousand-ton production capacity for natural high-purity DHA/EPA from algal and fish oils, technological upgrades, and global market expansion. This investment will further advance Yeast Biotech's innovation and industrialization in synthetic biology, bolstering its competitiveness in the international marketplace.
Latest News
Company Address: Room 304, 3rd Floor, Building 2, Qianwan Zhigu, Jiangnan Science City, Xiaoshan District, Hangzhou City, Zhejiang Province
Tel：
Email：
启用全局默认滚动动画 (向上滚动)
图片alt标题设置： YEAST BIOTECH
表单验证提示文本： Content cannot be empty!
循环体没有内容时： Sorry, no matching items were found.
CSS / JS 文件放置地